RBC Capital analyst Leonid Timashev raised the firm’s price target on Compass Pathways (CMPS) to $21 from $16 and keeps an Outperform rating on the shares. Following the firm’s Psychedelics Symposium, the firm is introducing a few changes to its CMPS model to better reflect the attitudes of key opinion leaders and companies on pricing, as well as the barriers to generic entry in the emerging innovative psychedelic therapy landscape, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- 3 ‘Strong Buy’ Stocks to Buy Today,1/9/2026, According to Top Analysts
- De-Risked Clinical Profile and Growing Commercial Infrastructure Support Buy Rating on COMPASS Pathways’ COMP360
- Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
- Advancing COMP360 From Binary Clinical Risk to Scaled Commercial Opportunity: Buy Rating Reaffirmed on De-Risked TRD Launch and PTSD Upside
- COMPASS Pathways expands Hercules loan facility for runway